Peter Farrell - ResMed Insider

ResMed -- USA Stock  

USD 101.17  2.37  2.40%

Non-Executive Chairman of the Board

Dr. Peter Farrell, Ph.D. is NonExecutive Chairman of the Board, Founder of the Company. Dr. Farrell also served as chief executive officer from July 1990 until December 2007, and from February 2011 until March 2013. Dr. Farrell served as executive chairman of the board from December 2007 until February 2011, and from March 2013 through December 2013. Since January 1, 2014, he was a nonofficer employee of ResMed. From July 1984 to June 1989, Dr. Farrell served as vice president, research and development at various subsidiaries of Baxter International, Inc., and from August 1985 to June 1989, he also served as managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. He also serves on the Visiting Committee of the Health Sciences Technology Program at the Massachusetts Institute of Technology and on the MIT Dean of Engineerings Advisory Council
Age: 74  Chairman Since 2014  Ph.D    
858-836-5000  http://www.resmed.com
Farrell serves on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions in the field of treatment with the artificial kidney. Since 2005, Dr. Farrell was a director of NuVasive, Inc., a NASDAQlisted company which develops and markets products for the surgical treatment of spine disorders. From 2007 through 2014, he was the nonexecutive chairman of the board of QRx Pharma, an ASXlisted specialty pharmaceutical company.

Peter Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 9.1 % which means that on every $100 spent on asset it made $9.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.29 % implying that it generated $15.29 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 50.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 1.26 demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on New York Stock Exchange. It employs 6000 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Director, MBA
Ronald Taylor, Director
Rob Douglas, President
Christopher Roberts, Director, MBA
Gary Pace, Director, Ph.D
Chris Roberts, Director, MBA
Robert Douglas, COO
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Brett Sandercock, CFO
Ron Taylor, Director
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA
Richard McHale, President
Donald Darkin, President

Stock Performance Indicators

Did you try this?

Run Money Flow Index Now
   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
View All  NextLaunch Money Flow Index

Trending Equities

Currently Active Assets on Macroaxis
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
AOI   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 24.75
REV   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 22.75
FB   
 NMS 
Purchased few shares of
few hours ago ago
Traded for 166.69
VMW   
 NYQ 
Purchased over 20 shares of
few hours ago ago
Traded for 134.7
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
Additionally take a look at Your Equity Center. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.